lonapegsomatropin vs somatrogon
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Growth Hormone Deficiency
Shared mechanism: Growth hormone receptor · full Growth Hormone Deficiency pipeline
lonapegsomatropin · Skytrofa
Marketed by Ascendis Pharma A/S and partners
NCT04615273 · Phase 3 · completed
This randomized Phase 3 trial assigned 264 adults with growth hormone deficiency to once-weekly lonapegsomatropin, matching placebo or open-label daily somatropin; the lonapegsomatropin and placebo arms were double-blind and formed the primary comparison. The primary endpoint, change in trunk percent fat measured by DXA at Week 38, was met: trunk fat fell by 1.68 percentage points on lonapegsomatropin and rose by 0.37 on placebo (difference -2.04, 95% CI -2.94 to -1.14, p<0.0001). The record reports no power calculation or planned enrolment.
Reported efficacy
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation (Up to 52 Weeks): Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation (Up to 52 Weeks): Lonapegsomatropin/Lonapegsomatropin — TEAEs: 48 Participants; Serious TEAEs: 7 Participants; TEAE Leading to Study Discontinuation: 2 Participants | Placebo/Lonapegsomatropin — TEAEs: 52 Participants; Serious TEAEs: 4 Participants; TEAE Leading to Study Discontinuation: 4 Participants | Somatropin/Lonapegsomatropin — TEAEs: 45 Participants; Serious TEAEs: 5 Participants; TEAE Leading to Study Discontinuation: 2 Participants (not_applicable)
Result source: NCT05171855
somatrogon · NGENLA
Marketed by Pfizer and partners
NCT03831880 · Phase 3 · completed
Randomized crossover comparison against daily Genotropin, and the primary measure of treatment burden (overall life interference score) was significantly lower with weekly somatrogon (difference -15.49 points, p<0.0001). The study was open-label and the outcome is a questionnaire answered by families who knew which treatment they were on, and it measures injection burden rather than growth.
Reported efficacy
Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire; Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire; Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire; Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire (Baseline up to Week 24): Overall life interference total score (DCOA 1), crossover: weekly somatrogon 8.63 vs daily Genotropin 24.13; difference -15.49 (95% CI -19.71 to -11.27), p<0.0001 (CT.gov posted results). (met)
Result source: NCT03831880
Results for Growth Hormone Deficiency
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
lonapegsomatropin: registry results are on file for Growth Hormone Deficiency, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lonapegsomatropin's landscape · somatrogon's landscape